Please login to the form below

Not currently logged in
Email:
Password:

Novartis US appeals halt generic Famvir

Novartis says that a US court halted Israeli-based Teva's sale of a generic version of its Famvir genital herpes treatment

Novartis has said that that a US court has halted Israeli-based Teva's sale of a generic version of its Famvir (famciclovir) genital herpes treatment.

The Swiss-headquartered company said the injunction by the US Court of Appeals for the Federal Circuit was issued on 8 September, two days after a district court in New Jersey denied Novartis' motion to stop Israel's Teva from marketing its version of the drug.

The injunction requires Teva to submit a response by 11 September 2007, Novartis revealed in a company statement.

Novartis shares were down 0.4 per cent at CHF 63.25 (USD 53.27) on the Zurich stock exchange on 10 September 2007.

10th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics